GlycoMimetics, Inc.
http://www.glycomimetics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GlycoMimetics, Inc.
GlycoMimetics Forges Ahead With Uproleselan In AML After Phase III Failure
The company said an NCI trial and a China study remain ongoing despite a Phase III study in relapsed/refractory disease failing, with an unusually long OS result in the control arm.
BIO’s New CEO Is Biotech Industry Veteran With Compelling Family Story, Ready To Take On The IRA
John Crowley will take the reins at BIO in March, about a year and a half after the departure of former CEO Michelle McMurry-Heath was announced.
Pfizer In Pole Position To Benefit From Novartis Sickle Cell Drug Setback
Pfizer joined Novartis as the market leader in sickle cell disease when it acquired Global Blood Therapeutics last year. The US giant's Oxbryta may now move ahead following a clinical and regulatory setback for the Swiss major's Adakveo.
Quick BIO CEO Departure Raises Questions About Direction For Next Leadership Pick
Michelle McMurry-Heath brought a science and regulatory background to the top post of the industry trade group in contrast to the political and lobbying focused careers of her predecessors. Her eventual successor may offer hints as to whether BIO thought that was a successful leadership strategy.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Drug Discovery Tools
- ADMET
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice